Company Profile

Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The Company's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).

Employees

Sector

Biotechnology & Medical Research

More about the company

31/01/24	Aravive, Inc.(NasdaqGS:ARAV) dropped from S&P TMI Index	CI
26/01/24	Aravive, Inc.(NasdaqGS:ARAV) dropped from NASDAQ Composite Index	CI
20/01/24	Wall Street Set to Open Higher Friday Ahead of Consumer Sentiment, Home Sales Data	MT
18/01/24	Aravive Shares Sink 53% After Hours on Plans to Voluntarily Terminate Listing on Nasdaq Global Select Market	MT
18/01/24	Aravive, Inc. Announces Termination of Rudy C. Howard as Chief Financial Officer	CI
18/01/24	Aravive, Inc. Announces Termination of Gail McIntrye as Chief Executive Officer	CI
18/01/24	Aravive, Inc. Announces Board and Committee Resignations	CI
10/11/23	Aravive, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
22/08/23	Cantor Fitzgerald Downgrades Aravive to Neutral From Overweight, Adjusts Price Target to $0.25 From $18	MT
22/08/23	Aravive, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
04/08/23	Top Midday Decliners	MT
03/08/23	EF Hutton Downgrades Aravive to Hold From Buy, Adjusts Price Target to $1 From $10	MT
03/08/23	HC Wainwright Downgrades Aravive to Neutral From Buy	MT

22/08/23	Cantor Fitzgerald Downgrades Aravive to Neutral From Overweight, Adjusts Price Target to $0.25 From $18	MT
03/08/23	EF Hutton Downgrades Aravive to Hold From Buy, Adjusts Price Target to $1 From $10	MT
03/08/23	HC Wainwright Downgrades Aravive to Neutral From Buy	MT
03/08/23	William Blair Downgrades Aravive to Market Perform From Outperform	MT
03/08/23	BTIG Downgrades Aravive to Neutral From Buy	MT

18/01/24	Aravive, Inc. to Delist from The Nasdaq Stock Market	AQ
19/10/23	The Street Reports: Guide to Penny Stocks Look Now! CLNV, ARAV, RDHL, ATHX, EPAZ	AQ
03/08/23	Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer	AQ
28/07/23	Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023	AQ
14/07/23	Aravive to Participate in William Blair’s Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023	AQ

Manager	Title	Age	Since
Marek Ciszewski IRC	Investor Relations Contact	-	-
Maria Petrini PRN	Corporate Officer/Principal	-	10/04/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/4/23	Maria Petrini	Free	Executive/Senior Manager	400,000	0.6684%
1/2/23	Robert B. Geller	Free	Chief Technology Officer	400,000	0.6686%
1/2/23	Leonard Dove	Free	Chief Operating Officer	400,000	0.6686%

Aravive, Inc. Stock

Stocks

ARAV

US03890D1081

Biotechnology & Medical Research

Latest news : Aravive, Inc.

Analysts' recommendations: Aravive, Inc.

Press Releases: Aravive, Inc.

Quotes and Performance

Managers and Directors: Aravive, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARAVIVE, INC.	-13.39%	-23.18%	-	-	2.95M
WUXI APPTEC CO., LTD.	+8.49%	+20.55%	+69.74%	+109.30%	68.12B
ARGENX SE	+1.25%	+2.44%	+32.55%	+72.63%	55.18B
INSMED INCORPORATED	-1.09%	+32.96%	+19.95%	+499.45%	28.63B
BIONTECH SE	+2.72%	+3.41%	-15.88%	-4.90%	23.53B
WUXI BIOLOGICS (CAYMAN) INC.	+10.83%	+18.38%	+52.76%	+4.58%	23.99B
GENMAB A/S	+6.50%	+7.56%	+38.20%	-21.33%	18.45B
PHARMAESSENTIA CORPORATION	-3.88%	+16.98%	+199.30%	+354.30%	15.83B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+6.20%	+11.51%	+34.94%	+681.88%	16.44B
EXELIXIS, INC.	+3.58%	+1.96%	+44.61%	+167.01%	13.4B
Average	+2.12%	+11.68%	+52.91%	+206.99%	29.28B
Weighted average by Cap.	+4.36%	+13.10%	+49.48%	+168.49%